TY - JOUR
T1 - Hepatobiliary cancers, Version 2.2021
AU - Benson, Al B.
AU - D'Angelica, Michael I.
AU - Abbott, Daniel E.
AU - Anaya, Daniel A.
AU - Anders, Robert
AU - Are, Chandrakanth
AU - Bachini, Melinda
AU - Borad, Mitesh
AU - Brown, Daniel
AU - Burgoyne, Adam
AU - Chahal, Prabhleen
AU - Chang, Daniel T.
AU - Cloyd, Jordan
AU - Covey, Anne M.
AU - Glazer, Evan S.
AU - Goyal, Lipika
AU - Hawkins, William G.
AU - Iyer, Renuka
AU - Jacob, Rojymon
AU - Kelley, R. Kate
AU - Kim, Robin
AU - Levine, Matthew
AU - Palta, Manisha
AU - Park, James O.
AU - Raman, Steven
AU - Reddy, Sanjay
AU - Sahai, Vaibhav
AU - Schefter, Tracey
AU - Singh, Gagandeep
AU - Stein, Stacey
AU - Vauthey, Jean Nicolas
AU - Venook, Alan P.
AU - Yopp, Adam
AU - McMillian, Nicole R.
AU - Hochstetler, Cindy
AU - Darlow, Susan D.
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/5
Y1 - 2021/5
N2 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
AB - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
UR - http://www.scopus.com/inward/record.url?scp=85106858883&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0022
DO - 10.6004/jnccn.2021.0022
M3 - Review article
C2 - 34030131
AN - SCOPUS:85106858883
SN - 1540-1405
VL - 19
SP - 541
EP - 565
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5
ER -